Neumega recombinant human interleukin-11 data

Evaluation of the first 12 patients in a Phase I trial of rhIL-11indicated the agent was able to boost platelet counts. The intermediate doses of 25 to 50 ug/kg/day increased platelet levels sufficiently to prevent chemotherapy-induced platelet losses, the study scientists concluded.

The doses tested, 10, 25, 50, and 75 ug/kg/day, were associated with edema in the patients, who were receiving chemotherapy in multiple cycles for breast cancer. One patient withdrew after the second cycle of combined chemotherapy and rhIL-11 at the 75 ug/kg dose, due to the edema. Fatigue, muscle aches, and joint aches were reported by all patients given this highest dose. ...